Potential Use of Inducible TLS
A summary schematic of potential therapeutic use of inducible tertiary lymphoid structures (iTLS). iTLS preparations may include cellular components such as dendritic cells, or reticular fibroblasts modified to engage the LTBR pathway, or co-delivered with soluble LTBR-ligands via a delayed-release platform such as liposomes, nanoparticles, or micelles. Injectable or implantable iTLS preparations could be administered at the site of tumor resection to induce TLS and subsequently control residual disease or counteract reoccurrence.